Experimental cancer drug TAK-500 tested in 61 patients – study halted early

NCT ID NCT05070247

Terminated Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAK-500 (a drug that stimulates the immune system) and pembrolizumab (an immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for several advanced cancers that have stopped responding to standard therapies.
What could go wrong: The study was terminated early, so results are limited. It was a small, early-phase trial, so even if safe, effectiveness is uncertain. Side effects from immune stimulation can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm clear cell renal carcinoma esophageal adenocarcinoma esophageal cancer Esophageal Neoplasms gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma hepatocellular carcinoma kidney cancer Liver Neoplasms malignant pancreatic neoplasm mesothelioma nasopharyngeal carcinoma nasopharyngeal carcinoma, susceptibility to, 1 nasopharyngeal neoplasm non-small cell lung carcinoma pancreatic adenocarcinoma pancreatic neoplasm pediatric hepatocellular carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER ESOPHAGEAL CANCER GASTRIC CANCER HEPATOCELLULAR CANCER KIDNEY CANCER MESOTHELIOMA NASOPHARYNGEAL CANCER NON-SMALL CELL LUNG CANCER (NSCLC), NON-SQUAMOUS PANCREATIC CANCER SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
New York University

New York, New York, 10016-4744, United States
Northwestern

Chicago, Illinois, 60611, United States
START South Texas Accelerated Research Therapeutics

San Antonio, Texas, 78229, United States
Sarah Cannon Cancer Institute

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute

Denver, Colorado, 80218, United States
Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
Univeristy of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of California San Diego

La Jolla, California, 92093, United States
University of Colorado - Anschutz Medical Campus - PPDS

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.